Projekt

SAKK 19/16:Binimetinib, pemetrexed and cisplatin, followed by maintenance with binimetinib and pemetrexed, in patients with advanced non-small cell lung cancer with KRAS mutationsA multicenter phase IB trial

Automatisch geschlossen · 2017 bis 2019

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als Hauptzentrum
Bereiche
Status
Automatisch geschlossen
Start
2017
Ende
2019
Finanzierungsart
SAKK
Studiendesign
Phase IB
Schlagwörter (Tags)
Advanced NSCLC, first line, KRAS mutation, MEK Inhibi-tor, combination with cisplatin and pemetrexed
Projektpartner
SAKK, Array BioPharma Inc.
Kurzbeschreibung/Zielsetzung

There is a need for more effective therapies for patients with advanced NSCLC driven by the RAS/MEK/ERK pathway. These tumors are generally aggressive, are almost exclusively of non-squamous histology, and represent the largest group of patients with advanced NSCLC harboring specific amutation in Western populations. Based on recent preclinical and clinical evidence, mitogen-activated protein kinase kinase (MEK)-inhibition plus first-line chemotherapy is a promising new treatment for patients with NSCLC and KRAS.